Pharma’s R&D Dilemma: Blockbuster Costs Without Blockbuster Revenues
January 5th 2017According to a Deloitte report, the industry’s return on its research investment has been steadily slipping for the past six years. The conclusion? Fundamental change may no longer be a given, but a necessity for the industry